Advertisement
Advertisement
U.S. Markets open in 9 hrs 24 mins
Advertisement
Advertisement
Advertisement
Advertisement

ContraFect Corporation (CFRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0700-0.2700 (-8.08%)
At close: 04:00PM EDT
3.4200 +0.35 (+11.40%)
After hours: 06:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.3400
Open3.3500
Bid3.0300 x 3200
Ask3.4200 x 1000
Day's Range3.0200 - 3.4250
52 Week Range2.1100 - 4.7550
Volume85,421
Avg. Volume125,362
Market Cap120.751M
Beta (5Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.6580
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.92
  • GlobeNewswire

    Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections

    YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing that the Company’s lead product candidate, exebacase, which has been designated as a Breakthrough Therapy for developm

  • GlobeNewswire

    ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022

    YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to present two posters at the ASM Microbe Conference to be held in Washington, D.C. from June 9-13, 2022. The

  • Zacks Small Cap Research

    CFRX: Results from Interim Futility Analysis in July 2022…

    By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Update on Phase 3 DISRUPT Trial ContraFect, Corp. (NASDAQ:CFRX) is currently conducting the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) trial of exebacase in patients with Staphylococcus aureus bacteremia, including right-sided endocarditis. The DISRUPT trial is a randomized, double

Advertisement
Advertisement